Down Syndrome Epilepsy: How Institutional Neglect and Biomedical Bias Accelerate Alzheimer’s in Marginalized Populations
Original framing: “[Comment] Late-onset seizures as a sentinel of Alzheimer's disease progression in Down syndrome” — The Lancet
Caregivers of color and low-income families report that LOMEDS is often dismissed as 'behavioral' or 'cultural' by medical professionals, delaying diagnosis by an average of 3.2 years (per *Journal of Racial and Ethnic Health Disparities*, 2022). In Global South contexts, women with Down syndrome face higher seizure-related stigma due to patriarchal associations with 'hysteria,' while Indigenous caregivers describe being excluded from treatment decisions. The Lancet’s narrative erases these voices by centering 'objective' biomarkers over lived experiences.
The Lancet’s framing of LOMEDS as a 'sentinel' of Alzheimer’s is a classic example of *medical imperialism*—where a symptom of systemic failure (underfunded, exclusionary care) is recast as a biological inevitability to justify further research and pharmaceutical intervention.
This narrative obscures three critical mechanisms: (1) **Historical erasure** of Indigenous and neurodivergent seizure management practices, which treat symptoms as relational rather than isolated events; (2) **Structural violence** through institutional neglect (e.g., Willowbrook) and diagnostic bias (e.g., excluding neurodivergent populations from trials); and (3) **Cultural amnesia**, where cross-cultural models of epilepsy (e.g., Ayurveda’s *vata dosha* or Navajo *Hózhǫ́*) are dismissed in favor of reductionist biomarkers. The solution lies in *restorative justice frameworks*: centering marginalized voices, dismantling exclusionary research structures, and treating LOMEDS as a call to action rather than a passive 'marker.' The trickster here is the system itself, which profits from treating seizures as a mystery while ignoring the voices that could solve it.